References
- 1Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: A review. JAMA. 2022; 328(1): 57–68. DOI: 10.1001/jama.2022.10233
- 2Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381(9861): 142–51. DOI: 10.1016/S0140-6736(12)61229-X
- 3Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011; 41(6 Suppl. 4): S398–405. DOI: 10.1016/j.amepre.2011.09.013
- 4Odame I. Perspective: we need a global solution. Nature. 2014; 515(7526): S10. DOI: 10.1038/515S10a
- 5Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010; 115(17): 3447–52. DOI: 10.1182/blood-2009-07-233700
- 6Regional Committee for Africa. Sickle-Cell Disease: A strategy for the WHO African Region. WHO; 2011. WHO Publication AFR/RC60/8. Accessed March 2023. Sickle-Cell Disease: a strategy for the WHO African Region.
- 7Chhabria P. How can we deliver sustainable healthcare? 3 industry leaders lay out solutions; 2022. Accessed March 2023.
https://www.weforum.org/agenda/2022/09/3-industry-leaders-lay-out-solutions-to-better-protect-global-health-systems . - 8Regional Office for Africa. African health ministers launch drive to curb sickle cell disease toll. WHO African Region; 2022. Accessed March 2023. African health ministers launch drive to curb sickle cell disease toll | WHO | Regional Office for Africa.
- 9Rockers PC, Laing RO, Ashigbie PG, et al. Effect of Novartis access on availability and price of non-communicable disease medicines in Kenya: A cluster-randomised controlled trial. Lancet Glob Health. 2019; 7(4): e492–e502. DOI: 10.1016/S2214-109X(18)30563-1
- 10Archer NM, Inusa B, Makani J, et al. Enablers and barriers to newborn screening for sickle cell disease in Africa: results from a qualitative study involving programmes in six countries. BMJ Open. 2022; 12(3):
e057623 . DOI: 10.1136/bmjopen-2021-057623 - 11United Nations, Department of Economic and Social Affairs. Multi-stakeholder partnerships. Accessed March 2023.
Multi-stakeholder partnerships and voluntary commitments | Department of Economic and Social Affairs . - 12Ohene-Frempong K, Segbefia C, Spector J, et al. HemaSphere 2022; 6:16. DOI: 10.1097/01.HS9.0000821484.39112.40
- 13Manji I, Pastakia SD. Novartis Access: A small step towards increased access for non-communicable disease care. Lancet Glob Health. 2019; 7(4): e398–e99. DOI: 10.1016/S2214-109X(19)30049-X
- 14Horton R. Offline: Global health and the private sector. Lancet. 2018; 391(10136): 2196. DOI: 10.1016/S0140-6736(18)31253-4